Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
Federal Reserve Chairman Jerome Powell said on Wednesday that Facebook spoke to the central bank about the digital currency called LibraThe Fedread more
American Airlines is the first major U.S. airline to order Airbus' new long-range, single aisle aircraft.Paris Air Showread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
Employees spoke out on issues such as forced arbitration, workplace equity and Project Dragonfly at Alphabet's annual shareholder meeting.Technologyread more
Beyond Meat has blown up. The plant-based meat company is now larger than 80 S&P 500 companies, including Macy's, Xerox and Mylan.Trading Nationread more
Oracle found revenue growth from cloud applications in its fiscal fourth quarter, which helped it surpass analysts' expectations.Technologyread more
The deal for Perfect Bar's parent gives Mondelez a further foothold in snacking, as more people eat on-the-go.Food & Beverageread more
Chesley "Sully" Sullenberger told a congressional panel that pilots should receive simulator training before flying the Boeing 737 Max.Airlinesread more
Britain's biggest drugmaker is paying $75 a share for the business, an 110 percent premium to the 30-day average price. News of the lofty valuation sent GSK shares down 4 percent on Monday.
The deal gives GSK a marketed product for ovarian cancer, Zejula, which belongs to the promising new class of medicines called poly ADP ribose polymerase (PARP) inhibitors. GSK's U.K. rival, AstraZeneca, sells the rival PARP drug Lynparza.
Chief Executive Emma Walmsley has made replenishing GSK's medicines cabinet her top priority and the company signalled its intention to make more acquisitions in April, when it hired a key deal-maker from Roche's Genentech unit.
GSK has lagged behind rivals in recent years in producing multibillion-dollar blockbusters and it largely sat out a spate of deal-making by rival drugmakers under previous CEO Andrew Witty.
GSK said buying Tesaro would weigh on adjusted earnings for the first two years by mid to high single digit percentage rates, but the acquisition should be accretive by 2022.
Zejula's revenues in its current approved indication as second-line maintenance treatment for ovarian cancer were $166 million in the nine months to September.